- Home
- CPRX vs TSLX Comparison
CPRX vs TSLX Comparison
Compare CPRX & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRX
- TSLX
- Stock Information
- Founded
- CPRX 2002
- TSLX 2010
- Country
- CPRX United States
- TSLX United States
- Employees
- CPRX N/A
- TSLX N/A
- Industry
- CPRX Biotechnology: Pharmaceutical Preparations
- TSLX Investment Managers
- Sector
- CPRX Health Care
- TSLX Finance
- Exchange
- CPRX Nasdaq
- TSLX Nasdaq
- Market Cap
- CPRX 2.6B
- TSLX 2.2B
- IPO Year
- CPRX 2006
- TSLX 2014
- Fundamental
- Price
- CPRX $21.29
- TSLX $22.55
- Analyst Decision
- CPRX Strong Buy
- TSLX Buy
- Analyst Count
- CPRX 5
- TSLX 9
- Target Price
- CPRX $33.20
- TSLX $23.67
- AVG Volume (30 Days)
- CPRX 1.4M
- TSLX 632.7K
- Earning Date
- CPRX 11-05-2025
- TSLX 11-04-2025
- Dividend Yield
- CPRX N/A
- TSLX 9.07%
- EPS Growth
- CPRX 183.96
- TSLX N/A
- EPS
- CPRX 1.65
- TSLX 2.01
- Revenue
- CPRX $558,499,000.00
- TSLX $474,291,000.00
- Revenue This Year
- CPRX $16.59
- TSLX N/A
- Revenue Next Year
- CPRX $8.80
- TSLX N/A
- P/E Ratio
- CPRX $12.72
- TSLX $11.20
- Revenue Growth
- CPRX 28.55
- TSLX 0.15
- 52 Week Low
- CPRX $19.05
- TSLX $18.58
- 52 Week High
- CPRX $26.58
- TSLX $25.17
- Technical
- Relative Strength Index (RSI)
- CPRX 57.67
- TSLX 53.51
- Support Level
- CPRX $20.66
- TSLX $21.15
- Resistance Level
- CPRX $21.55
- TSLX $22.04
- Average True Range (ATR)
- CPRX 0.57
- TSLX 0.45
- MACD
- CPRX 0.05
- TSLX 0.18
- Stochastic Oscillator
- CPRX 84.24
- TSLX 94.44
About CPRX Catalyst Pharmaceuticals Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers three drug products, FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.